<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04746937</url>
  </required_header>
  <id_info>
    <org_study_id>NTZ in Prevention of SBP</org_study_id>
    <nct_id>NCT04746937</nct_id>
  </id_info>
  <brief_title>Nitazoxanide in Prevention of Secondary Spontaneous Peritonitis</brief_title>
  <official_title>Clinical Study to Evaluate the Possible Efficacy and Safety of Nitazoxanide in Secondary Prevention of Spontaneous Bacterial Peritonitis in Cirrhotic Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tanta University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tanta University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      the study is to evaluate the possible efficacy and safety of nitazoxanide as an adjuvant&#xD;
      therapy in the secondary prevention of SBP in patient with cirrhosis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      due to high recurrence rate of spontaneous bacterial peritonitis , we will study and evaluate&#xD;
      the possible efficacy and safety of NTZ as an adjuvant therapy in the secondary prevention of&#xD;
      SBP in patient with cirrhosis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 2021</start_date>
  <completion_date type="Anticipated">May 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized Double-Blind Placebo-Controlled study</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Prevention of Secondary Spontaneous Bacterial Peritonitis</measure>
    <time_frame>3 months</time_frame>
    <description>Reduction in incidence of secondary Spontaneous Bacterial Peritonitis (SBP) compared to control group</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Biological Biomarkers</measure>
    <time_frame>3 months</time_frame>
    <description>Measurement of Tumor necrosis factor alfa , Procalcitonin(PCT), C-Reactive protein(CRP) and Erythrocyte sedimentation rate(ESR) with further calculation of PEC index [PEC index = PCT Ã— (ESR + CRP)] before and after trial period</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Spontaneous Bacterial Peritonitis</condition>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>They will receive standard therapy plus placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nitazoxanide Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>They will receive standard therapy plus nitazoxanide</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nitazoxanide</intervention_name>
    <description>nitazoxanide adjuvant to standard therapy</description>
    <arm_group_label>Nitazoxanide Group</arm_group_label>
    <other_name>NTZ</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Norfloxacin</intervention_name>
    <description>Standard therapy</description>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_label>Nitazoxanide Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients aged 21 - 65 years old with cirrhosis and ascites who had at least one&#xD;
             previous confirmed episode of spontaneous bacterial peritonitis.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Exclusion criteria included active gastrointestinal bleeding Hepatic encephalopathy&#xD;
             (&gt;grade 2) Hepatocellular carcinoma (HCC) or other malignancies Allergy to used&#xD;
             medications.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sahar M. Elhagar, Professor</last_name>
    <role>Study Director</role>
    <affiliation>Supervisor for my master degree</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>eslam M. Altaras</last_name>
    <phone>00201010730130</phone>
    <email>PG_88188@pharm.tanta.edu.eg</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>tarek M. Mostafa, A. Professor</last_name>
    <phone>00201154594035</phone>
    <email>Tarek.mostafa@pharm.tanta.edu.eg</email>
  </overall_contact_backup>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 5, 2021</study_first_submitted>
  <study_first_submitted_qc>February 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 10, 2021</study_first_posted>
  <last_update_submitted>February 8, 2021</last_update_submitted>
  <last_update_submitted_qc>February 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tanta University</investigator_affiliation>
    <investigator_full_name>Eslam Mostafa Elasawy AlTaras</investigator_full_name>
    <investigator_title>Clinical Pharmacist</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peritonitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nitazoxanide</mesh_term>
    <mesh_term>Norfloxacin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

